AI-designed drug candidates are entering clinical trials, quantum computers are outperforming classical systems on specific problems, and protein structure prediction has solved challenges that occupied structural biologists for decades. The transformation of the scientific method is underway.
After a decade of overhyped promises, microbiome science is producing reproducible clinical results in specific conditions. The interventions that work, and why they work, reveal a biology far stranger and more consequential than the popular science version.
Google's Willow chip and subsequent advances have compressed the timeline for fault-tolerant quantum computing by a decade. The industries that depend on current encryption standards should be treating this as an active risk, not a theoretical one.
Epidemiologists have identified a set of measurable signals that historically precede major zoonotic spillover events. Several of them are currently elevated.
Viruses don't want anything, of course. But thinking about viral evolution as if they did — as entities with strategies and trade-offs — turns out to be one of the most productive frameworks in modern biology.
A new generation of neuroscientists believes it can selectively erase traumatic memories. They may be right. The harder question is whether they should.
GLP-1 drugs are the most significant advance in obesity medicine in decades. They are also revealing how little we understood about obesity — and how much we still don't.
Billions are flowing into research that promises to add decades to the human lifespan. The science is more serious than the hype — and more uncertain than the investors admit.
Dr. Amara Singh··12 min
The Auguro Daily
The signals worth watching today
Every weekday morning: the signals emerging across geopolitics, markets, technology, and society — interpreted, not just reported.